Weihong Luan1, Haozhan Yuan1, Wei Hou2, Jing Li2, Liping Liu2. 1. Otolaryngology Head and Neck Surgery, Xianyang First People's Hospital No. 10, Biyuan Road, Xianyang 712000, Shaanxi Province, China. 2. Otolaryngology, The Affiliated Hospital of Shaanxi University of Chinese Medicine No. 2, Weiyang West Road, Xianyang 712000, Shaanxi Province, China.
Abstract
OBJECTIVE: To explore the effect of nimotuzumab combined with Taxol + Cisplatin (TP) regimen induction chemotherapy and sequential concurrent chemoradiotherapy on the improvement of curative effect and prognosis of patients with locally advanced nasopharyngeal carcinoma. METHOD: A retrospective analysis was performed on 91 patients with locally advanced nasopharyngeal carcinoma who were admitted to our hospital from February 2017 to February 2019, of which 41 patients received TP induction chemotherapy were assigned to control group (CG), and the remaining 50 patients received nimotuzumab on the basis of control group were assigned to observation group (OG). Both groups of patients received cisplatin chemotherapy concurrently with intensity-modulated radiotherapy (IMRT). Comparisons were made between the two group in terms of clinical efficacy, serum markers squamous cell carcinoma-associated antigen (SCCAg), cytokeratin 19 fragment 21-1 (CYFRA21-1), adverse reactions, and 3-year survival of the patients. RESULTS: Remission rate of cervical lymph nodes in OG was better than that in CG (P<0.05). After treatment, SCC-Ag and CYFRA21-1 decreased significantly in both groups, while indexes in OG were markedly lower compared to CG (P<0.05). During induction therapy and concurrent chemoradiotherapy, no notable difference was observed in short-term or long-term adverse reactions between the two groups (P>0.05). And Cox regression analysis found that clinical stage and treatment were independent factors affecting the prognosis of patients with disease-free survival (PFS). CONCLUSION: Nimotuzumab combined with TP regimen induction chemotherapy and sequential concurrent chemoradiotherapy can improve the curative effect of patients with locally advanced nasopharyngeal carcinoma. AJTR
OBJECTIVE: To explore the effect of nimotuzumab combined with Taxol + Cisplatin (TP) regimen induction chemotherapy and sequential concurrent chemoradiotherapy on the improvement of curative effect and prognosis of patients with locally advanced nasopharyngeal carcinoma. METHOD: A retrospective analysis was performed on 91 patients with locally advanced nasopharyngeal carcinoma who were admitted to our hospital from February 2017 to February 2019, of which 41 patients received TP induction chemotherapy were assigned to control group (CG), and the remaining 50 patients received nimotuzumab on the basis of control group were assigned to observation group (OG). Both groups of patients received cisplatin chemotherapy concurrently with intensity-modulated radiotherapy (IMRT). Comparisons were made between the two group in terms of clinical efficacy, serum markers squamous cell carcinoma-associated antigen (SCCAg), cytokeratin 19 fragment 21-1 (CYFRA21-1), adverse reactions, and 3-year survival of the patients. RESULTS: Remission rate of cervical lymph nodes in OG was better than that in CG (P<0.05). After treatment, SCC-Ag and CYFRA21-1 decreased significantly in both groups, while indexes in OG were markedly lower compared to CG (P<0.05). During induction therapy and concurrent chemoradiotherapy, no notable difference was observed in short-term or long-term adverse reactions between the two groups (P>0.05). And Cox regression analysis found that clinical stage and treatment were independent factors affecting the prognosis of patients with disease-free survival (PFS). CONCLUSION: Nimotuzumab combined with TP regimen induction chemotherapy and sequential concurrent chemoradiotherapy can improve the curative effect of patients with locally advanced nasopharyngeal carcinoma. AJTR
Authors: Guohui Xu; Jinyi Lang; Yecai Huang; Mei Feng; Xuegang Yang; Jie Zhou; Lu Li; Ke Xu Journal: Cancer Manag Res Date: 2020-05-06 Impact factor: 3.989